title: What is the appropriate duration of dual antiplatelet therapy?
abstract: Healthcare providers often are faced with the challenge of determining an appropriate length of dual antiplatelet therapy (DAPT) for patients who have had percutaneous coronary intervention and stent placement. This is an especially challenging clinical decision for patients with drug-eluting stents, as several studies show different results when assessing risk and benefit.
authors.affiliation: Cortney M. Mospan is an assistant professor of pharmacy practice at East Tennessee State University's Bill Gatton College of Pharmacy in Johnson City, Tenn. She also serves as a clinical pharmacist with Mooney's Discount Pharmacy. The author has disclosed no potential conflicts of interest, financial or otherwise.
authors.forename: Cortney M
authors.initials: CM
authors.lastname: Mospan
mesh_terms: D001241:Aspirin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D006801:Humans; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects* / Q000379:methods; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D011183:Postoperative Complications / Q000517:prevention & control*; D011184:Postoperative Period; D011725:Pyridines / Q000008:administration & dosage; D018570:Risk Assessment; D012307:Risk Factors; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*; D013997:Time Factors
chemical_list: D010975:Platelet Aggregation Inhibitors; D011725:Pyridines; C446540:thienopyridine; D001241:Aspirin